Abstract
Traditionally, the development of drugs has focused on small molecule therapeutics. However, with recent advances in recombinant protein technology the potential of proteins as therapeutics is starting to be realized. Already there are protein drugs on the market, including naturally occurring proteins, engineered proteins and proteins introduced into the patient by way of gene therapy. The next generation of such drugs are likely to be designed molecules, proteins devised from scratch and specifically tailored to have a required 3-dimensional structure and biochemical function. The key to such de novo design is the extensive bioinformatics knowledge that has been obtained from experimentally determined protein structures during the past 40-50 years. The knowledge is far from complete, for example, the protein folding problem has not yet been completely solved. Despite this, bioinformatics plays a crucial role in protein design, as is outlined in this review, and a number of de novo protein structures have been successfully designed in recent years. Some examples of these successes, which are available in the Protein Data Bank, are presented. They suggest that carefully designed protein therapeutics are a genuine prospect for the future.
Keywords: Bioinformatics, Protein Design
Current Pharmaceutical Biotechnology
Title: Bioinformatics and Protein Design
Volume: 3 Issue: 4
Author(s): Roman A. Laskowski and A.W. Edith Chan
Affiliation:
Keywords: Bioinformatics, Protein Design
Abstract: Traditionally, the development of drugs has focused on small molecule therapeutics. However, with recent advances in recombinant protein technology the potential of proteins as therapeutics is starting to be realized. Already there are protein drugs on the market, including naturally occurring proteins, engineered proteins and proteins introduced into the patient by way of gene therapy. The next generation of such drugs are likely to be designed molecules, proteins devised from scratch and specifically tailored to have a required 3-dimensional structure and biochemical function. The key to such de novo design is the extensive bioinformatics knowledge that has been obtained from experimentally determined protein structures during the past 40-50 years. The knowledge is far from complete, for example, the protein folding problem has not yet been completely solved. Despite this, bioinformatics plays a crucial role in protein design, as is outlined in this review, and a number of de novo protein structures have been successfully designed in recent years. Some examples of these successes, which are available in the Protein Data Bank, are presented. They suggest that carefully designed protein therapeutics are a genuine prospect for the future.
Export Options
About this article
Cite this article as:
Laskowski A. Roman and Chan Edith A.W., Bioinformatics and Protein Design, Current Pharmaceutical Biotechnology 2002; 3 (4) . https://dx.doi.org/10.2174/1389201023378157
DOI https://dx.doi.org/10.2174/1389201023378157 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of Protein-Protein Interactions as Potential Drugs
Current Computer-Aided Drug Design Biological Function and Medicinal Research Significance of G-Quadruplex Interactive Proteins
Current Topics in Medicinal Chemistry Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Editorial: [Hot Topic: Therapeutic Antioxidants for Neurodegenerative Disease]
Recent Patents on CNS Drug Discovery (Discontinued) Novel Somatic Mutations of the CDH1 Gene Associated with Gastric Cancer: Prediction of Pathogenicity Using Comprehensive In silico Methods
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Current Psychopharmacology Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines
Current Drug Targets Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Meet the Editorial Board:
Technology Transfer and Entrepreneurship (Discontinued) RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Neuroprotection and Regeneration Strategies for Spinal Cord Repair
Current Pharmaceutical Design Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry Calpain and Its Involvement in the Pathophysiology of CNS Injuries and Diseases: Therapeutic Potential of Calpain Inhibitors for Prevention of Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders